Earlier contact-lens glucose sensors struggled with weak enzyme stability, slow tear absorption, and inconsistent sensitivity. By fine-tuning the hydrogel's nanopore structure and adding the HA-Au@Pt nanocatalyst, researchers cut response time nearly in half and lowered the glucose detection threshold roughly tenfold. In tests on diabetic rabbits and a human volunteer, the lens's readings correlated strongly with a standard glucometer (Pearson's correlation up to 0.95), and it maintained sensitivity for over 35 days with minimal drift. Cytotoxicity and corneal safety testing showed no inflammation or tissue damage.

For clinicians, a validated tear-glucose-to-blood-glucose correlation (with regression accuracy above 0.99 in this study) opens the door to non-invasive, continuous diabetes monitoring — particularly valuable for needle-averse patients, including children.

Because health data must be matched to the right person, the system uses a fingerprint scanner on the flush lever and a secondary scan for identification, since not everyone who uses the toilet is the one who flushes it. All data is de-identified and encrypted before being sent to a secure, HIPAA-compliant cloud system, where it can eventually feed into electronic health records.

Unlike a smartwatch, a toilet can't be forgotten on the nightstand. "Everyone uses the bathroom — there's really no avoiding it," Gambhir notes, which is precisely what makes it a compelling continuous monitoring platform. A pilot study with 21 participants demonstrated feasibility, though user-acceptance surveys show adoption will need careful, sensitive rollout — about half of prospective users reported being "somewhat" or "very" comfortable with the concept.

This is not a diagnostic replacement for a physician. Rather, it functions as an early-warning system: if a red flag (like blood in urine) appears, an app alerts the person's care team so a proper clinical work-up can follow.

Machine learning models trained on accelerometer data outperformed every other data type at distinguishing people with clinically diagnosed Parkinson's — and, notably, those in the pre-diagnostic "prodromal" stage — from the general population. According to lead researcher Dr. Cynthia Sandor, the reduction in movement speed detected before diagnosis was specific to Parkinson's and wasn't seen in other neurological conditions studied.

Continuous clinical monitoring for early neurodegeneration is normally constrained by cost, time, and access. Consumer smartwatches, already worn daily by hundreds of millions of people, offer a low-cost, passive way to gather exactly this kind of longitudinal movement data — without a single clinic visit.

The authors are clear that more validation is needed before this becomes a diagnostic tool. But for neurologists, it hints at a future where at-risk patients could be flagged for closer monitoring or early intervention trials years before symptoms would normally prompt a referral.

Of 2,155 people screened, 231 had a positive sensor reading or an irregular pulse. Following full analysis, 59 participants (2.7%) were confirmed or suspected to have AF — 39 of them previously undiagnosed, a newly detected AF yield of about 1.8%, comparable to rates reported in formal opportunistic AF screening programs. Sensitivity ranged from 0.70–0.93 and specificity from 0.93–0.97 across sensitivity analyses, broadly in line with previously validated performance of the MyDiagnostick device.

About 20% of ECGs were non-diagnostic, mostly due to movement artefact from shoppers naturally shifting their grip while pushing the trolley. The researchers suggest that a shorter recording window (30 seconds instead of 60) and a fixed single-contact grip point could substantially reduce this noise in future iterations.

For public health teams, this study is proof that opportunistic screening embedded into an everyday activity — grocery shopping — can reach people, including older adults and those in underserved communities, who might never take part in a formal cardiology screening clinic.

It uses a fingerprint scanner built into the flush lever, along with a secondary identification scan, to match each sample to the correct user. All data is de-identified before being stored in a secure, HIPAA-compliant cloud system.

Not on its own. Research from Cardiff University found that accelerometer data from wearables could help identify people at high risk of developing Parkinson's disease years before clinical symptoms appear, but a formal diagnosis still requires clinical assessment.

In the SHOPS-AF study, sensitivity ranged from 0.70 to 0.93 and specificity from 0.93 to 0.97, depending on the analysis method used. About 20% of readings were non-diagnostic due to movement artefact, an issue researchers say further refinement could reduce.

No. All four technologies are designed as early-detection and screening tools that flag potential issues for further clinical evaluation — not as substitutes for professional diagnosis or treatment.